The FDA released a 53-page analysis from Pfizer in which the drugmaker outlines data it says supports the authorization of a third dose of its COVID-19 vaccine.
Pfizer found five side effects to be most common after the third dose in its trial, which included 289 participants ages 18 to 55. They are listed below, along with the percentage of participants who reported experiencing these side effects:
- Injection site pain: 83 percent
- Fatigue: 63.7 percent
- Headache: 48.4 percent
- Muscle and joint pain: 39.1 percent
- Chills: 29.1 percent
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
